Pulse Biosciences (NASDAQ:PLSE) Announces Earnings Results

Pulse Biosciences (NASDAQ:PLSE) issued its earnings results on Thursday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07), FiscalAI reports. The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative return on equity of 100.22% and a negative net margin of 6,755.78%.

Here are the key takeaways from Pulse Biosciences’ conference call:

• nPulse AF catheter enrollment is ahead of schedule: The pivotal NANOPULSE-AF study surpassed the halfway point with more than 82 evaluable patients, and enrollment is now expected to finish in early October, despite expanding the target from 145 to 164 patients.
• Early clinical and workflow feedback remains highly favorable, with physicians reporting five to seven cases per day and ablation times as short as five to eight minutes. Management believes the resulting throughput and hospital economics could support significant adoption, though pivotal outcomes remain pending.
• European feasibility data for the cardiac catheter showed 96% freedom from AF at one year by 24-hour Holter monitoring, 90% freedom from recurrent AF, flutter, or tachycardia by Kaplan-Meier analysis, and a 1.7% serious adverse event rate across 177 patients. The company remains on track to submit for a CE mark in the second half of 2026 and potentially receive approval around mid-2027.
• Pulse strengthened its balance sheet through $57.5 million of net ATM proceeds, ending Q2 with $101.6 million in cash and extending its runway through key clinical and regulatory milestones. It also established a new $75 million ATM facility and received $1.8 million from warrant exercises.
• Spending and losses increased as the company accelerated clinical and product development, with Q2 GAAP operating expenses rising to $25.7 million and GAAP net loss reaching $24.7 million. Operating cash use rose to $18.7 million, while management expects quarterly non-GAAP expenses to remain near current levels.

Pulse Biosciences Stock Performance

Shares of NASDAQ PLSE traded up $4.17 during midday trading on Friday, hitting $42.41. 734,091 shares of the stock traded hands, compared to its average volume of 361,024. Pulse Biosciences has a one year low of $12.56 and a one year high of $45.90. The business has a 50 day moving average price of $29.01 and a two-hundred day moving average price of $23.64. The company has a market cap of $2.94 billion, a PE ratio of -35.94 and a beta of 1.61.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PLSE. Wall Street Zen lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Canaccord Genuity Group initiated coverage on Pulse Biosciences in a report on Thursday, June 4th. They issued a “buy” rating and a $32.00 target price for the company. Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.33.

Insiders Place Their Bets

In related news, CEO Paul A. Laviolette acquired 15,000 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $19.69 per share, with a total value of $295,350.00. Following the completion of the purchase, the chief executive officer directly owned 15,000 shares in the company, valued at $295,350. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert W. Duggan bought 660,233 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $19.69 per share, for a total transaction of $12,999,987.77. Following the acquisition, the director directly owned 48,211,433 shares of the company’s stock, valued at approximately $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 74.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pulse Biosciences

Several large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. boosted its stake in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after purchasing an additional 680 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Pulse Biosciences by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after purchasing an additional 1,300 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the period. Finally, Barclays PLC lifted its stake in Pulse Biosciences by 8.5% in the fourth quarter. Barclays PLC now owns 27,652 shares of the company’s stock valued at $380,000 after purchasing an additional 2,164 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.